ArticleCancer medicine2023
Establishment and application of a survival rate graph model based on biomarkers and imaging indexes after primary hepatocellular carcinoma resection.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary liver cancer (PLC) is a highly malignant disease. This study developed an effective and convenient tool to evaluate survival times of patients after hepatectomy, which can provide a reference point for clinical decisions.
methodsClinical and laboratory data of 243 patients with PLC after hepatectomy were collected. Univariate cox regression analysis, Lasso regression analysis and multivariate cox regression analysis were used to determine the best prediction index. Multivariate cox regression analysis was used to construct a survival prediction model. A receiver operating characteristic (ROC) curve, calibration curve and decision curve analysis (DCA) were used to verify the model. The patients in this model were divided into was divided into high-risk and low-risk groups according to the optimal cut-off value of the ROC curve for different prognostic years. Kaplan-Meier survival analysis and log-rank test were used to analyse the survival differences between the two groups.
resultsTumour size, portal vein thrombosis, distant metastasis, alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II levels were independent risk factors for overall survival (OS) after PLC surgery. The area under the concentration-time curve for 2-, 3- and 4-year survival of patients was 0.710, 0.825 and 0.919, respectively, with a good calibration of the Hosmer-Lemeshow test (p > 0.05) and net benefit. The mortality rates in patients with 2, 3 and 4 years of survival were 70.59%, 67.83% and 66.67% for the high-risk group and 21.84%, 22.50% and 22.67% for the low-risk group, respectively. The mortality rate of the high-risk group was significantly higher than that of the low-risk group (p < 0.05).
conclusionThe OS model of prognosis after PLC surgery constructed in this study can be used to predict the 2-, 3- and 4-year survival prognoses of patients, and patients with different prognosis years can be re-stratified so that they achieve more accurate and personalised assessment, thereby providing a reference point for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.